Inhibition of the TIM-1 and -3 signaling pathway ameliorates disease in a murine model of rheumatoid arthritis
Clinical and Experimental Immunology · 2024
DOI: 10.1093/cei/uxae056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Yuji Nozaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan. Hauptthemen laut MEDLINE: Hepatitis A Virus Cellular Receptor 2, Hepatitis A Virus Cellular Receptor 1, Arthritis, Rheumatoid, Signal Transduction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Members of the T-cell immunoglobulin and mucin (TIM) family, which is crucial for T-cell function, are implicated in autoimmunity. TIM-1 and -3 play distinct roles in autoimmunity, with TIM-1 acting as a costimulatory molecule and TIM-3 regulating Th1 responses. We investigated the therapeutic potential of anti-TIM-1 (RMT1-10) and anti-TIM-3 (RMT3-23) antibodies in an autoimmune arthritis model. Zymosan A was used to induce arthritis in female SKG mice. The arthritis scores, histology, mRNA expression, cytokine levels, micro-computed tomography, and flow cytometry results were obtained. The application of RMT1-10 reduced the arthritis scores, histological damage, and CD4+ T-cell infiltrations, and it suppressed interleukin (IL)-6 and -17A and reduced TIM-3 mRNA expressions. RMT3-23 also lowered arthritis severity, improved histology, and reduced serum levels of tumor necrosis factor (TNF)-α and IL-17A. RMT3-23 inhibited intracellular TNF-α and IL-6 and early apoptosis. An amelioration of autoimmune arthritis was achieved by blocking the TIM-1 and -3 signaling pathways via RMT1-10 and RMT3-23 administration, leading to a widespread decrease in inflammatory cytokines. Both antibodies exhibited therapeutic effects, suggesting TIM-1 and -3 as potential targets for rheumatoid arthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
- Department of Immunology, Juntendo University, School of Medicine, Bunkyo-ku, Tokyo, Japan.
ORCID-Profile: Yuji Nozaki
Zitieren
APA
Nozaki, Y., Akiba, H., Akazawa, H., Yamazawa, H., Ishimura, K., Kinoshita, K., & Matsumura, I. (2024). Inhibition of the TIM-1 and -3 signaling pathway ameliorates disease in a murine model of rheumatoid arthritis. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae056
Vancouver
Nozaki Y, Akiba H, Akazawa H, Yamazawa H, Ishimura K, Kinoshita K, et al. Inhibition of the TIM-1 and -3 signaling pathway ameliorates disease in a murine model of rheumatoid arthritis. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxae056
BibTeX
@article{Nozaki2024,
author = {Nozaki, Yuji and Akiba, Hisaya and Akazawa, Hiroki and Yamazawa, Hirotaka and Ishimura, Kaori and Kinoshita, Koji and Matsumura, Itaru},
title = {Inhibition of the TIM-1 and -3 signaling pathway ameliorates disease in a murine model of rheumatoid arthritis},
journal = {Clinical and Experimental Immunology},
year = {2024},
doi = {10.1093/cei/uxae056}
}
EUVIMED